Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult

[admin]

• TransCon PTH could, if approved, become the first hormone replacement therapy to address the underlying cause of hypoparathyroidism, an area of major unmet medical need for the estimated 70,000-90,000 adults living with chronic disease in the United States alone. • European MAA on track for Q4 2022 submission COPENHAGEN, Denmark, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administrat